B. Riley Securities initiated coverage on Ambrx Biopharma with a new price target
$AMAM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
B. Riley Securities initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00